Legend Biotech Corporation (LEGN)

Market Cap	7.36B
Revenue (ttm)	520.18M
Net Income (ttm)	-348.13M
Shares Out	183.45M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,232,762
Open	38.55
Previous Close	38.40
Day's Range	38.41 - 41.00
52-Week Range	37.40 - 70.13
Beta	0.11
Analysts	Strong Buy
Price Target	81.46 (+102.94%)
Earnings Date	Nov 12, 2024

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 1,826
• Stock Exchange: NASDAQ
• Ticker Symbol: LEGN
• Website: https://www.legendbiotech.com

Financial Performance

In 2023, Legend Biotech's revenue was $285.14 million, an increase of 143.70% compared to the previous year's $117.01 million. Losses were -$518.25 million, 16.1% more than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for LEGN stock is "Strong Buy." The 12-month stock price forecast is $81.46, which is an increase of 102.94% from the latest price.

Price Target

$81.46

(102.94% upside)

Analyst Consensus: Strong Buy